10 - 67 - SCLEREDEMA AND SCLEROMYXEDEMA Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Skin disorders that are characterized by increased mucin content, excessive collagen deposition, or fibrocyte hyperplasia are designated as

A

mucinoses, sclerosing disorders, or fibrosing disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what fibrocyte product predominates in pretibial myxedema?

A

excessive mucin production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what fibrocyte product predominates in scleroderma

A

collagen deposition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what fibrocyte product predominates in scleredema

A

excessive mucin and collagen deposition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

excessive mucin and depostition and fibrocyte hyperplasia

A

scleromyxedema and nephrogenic systemic fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fibroblasts are derived from CD____-positive hematopoietic precursors

A

CD34

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

scleredema is most common in what age groups?

A

chilhood or adolescence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

scleredema most commonly occurs after _____________

A

upper respiratory tract infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

associated conditions of scleredema

A

Postinfectious

Diabetes mellitus

Paraproteinemia

Also hyperparathyroidism, connective tissue disease, HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

most commonly identified URTI etiology for scleredema

A

Streptococcal infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

second most common presentation of scleredema

A

Diabetes mellitus–associated scleredema of adulthood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

clinical findings of scleredema

A

An acute onset of nonpitting induration of neck, shoulders, and upper back skin may be followed by involvement of the face and arms. Characteristically, the affected skin appears smooth and waxy, with tense dermal induration and prominent follicular ostia, at times imparting a “peau d’orange” appearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

clinical findings of Scleromyxedema (also, lichen myxedematosus)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

major fibroblast products that are increased in scleredema-affected skin

A

Type 1 collagen and hyaluronate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

The skin of the _________ is a favored site for scleredema,

A

upper trunk (especially the back)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

stains for mucin

A

Alcian blue, colloidal iron

17
Q

histopathologic findings of scleredema

A

Punch biopsies of affected skin reveal a nontapered (square) appearance on low power. The proportion of dermis in dramatically increased in comparison to adjacent nonaffected skin (Fig. 67-2A). A decreased number or higher placement of eccrine units may be appreciated. Fibroblasts are normal in number and morphology. The collagen bundles are slightly thickened and separated from each other by subtle deposits of mucin.

18
Q
A
19
Q

prognosis and clinical course of scleredema

A

Postinfectious scleredema usually abates in 1 to 2 years.

Scleredema associated with adult-onset diabetes tends to be protracted, although some patients appear to improve with better glucose control.

Gammopathy-associated scleredema is more chronic and can be resistant to many therapies.

20
Q

T/F Antibiotics do not appear to affect the course of postinfectious scleredema.

A

True

21
Q

Chronic, progressive condition characterized by dermal fibrosis and mucinosis and normal thyroid function.

A

SCLEROMYXEDEMA

22
Q

SCLEROMYXEDEMA is usually associated with what condition?

A

paraproteinemia (typically immunoglobulin G-kappa)

23
Q

Clinical variants of scleromyxedema

A

■ Generalized, confluent lichenoid eruption (scleromyxedema).

■ Discrete papular (rarely nodular) eruption on the trunk or extremities (lichen myxedematosus).

■ Localized or generalized lichenoid plaques (but distinct from plaque-like mucinosis/reticulated erythematous mucinosis).

■ Urticarial plaques

24
Q

Clinical findings of scleromyxedema

A
  • The generalized lichenoid eruption consists of numerous minute (1 to 3 mm) papules scattered on the extremities and the trunk.
  • Scleromyxedema presents with confluent lichenoid plaques. Individual lesions and plaques may exhibit marked erythema or hyperpigmentation. The face is involved in most cases, resulting in significant deformity, “bovine facies” (Fig. 67-3). The trunk and extremities are usually affected (Fig. 67-4A) and often results in decreased flexibility and range of motion in the involved areas
25
Q

classical histopathologic findings of scleromyxedema

A

The classical histopathologic findings in scleromyxedema consist of superficial to mid-dermal mucin deposition with admixed fibroblast proliferation.

26
Q

prognosis and clinical course of scleromyxedema

A

Localized, “self-healing” variants are usually confined to the skin and are self-limiting. However, prospective followup and caution is advised as some cases fitting criteria for localized disease have been associated with internal organ involvement or progression to more generalized disease (so-called atypical papular mucinosis).

Scleromyxedema usually follows a chronic and progressive clinical course with more systemic organ and tissue involvement, and a poor outcome is expected.

Respiratory failure, cerebral disease, and infection usually lead to a gradual decline and death.

26
Q

This medication had been used for scleromyxedema for decades to treat scleromyxedema with variable efficacy

A

Melphalan

27
Q

Therapeutic options for patients with scleromyxedema

A

Agents or therapies with reported efficacy include: glucocorticoids, 24 intravenous immunoglobulin, 25 thalidomide, 26 extracorporeal photophoresis, 27 interferon-α, 28 combination chemotherapy, 29and psoralen and ultraviolet A